Chronic blockade of endogenous atrial natriuretic polypeptide (ANP) by monoclonal antibody against ANP accelerates the development of hypertension in spontaneously hypertensive and deoxycorticosterone acetate-salt-hypertensive rats.
Open Access
- 1 July 1989
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 84 (1) , 145-154
- https://doi.org/10.1172/jci114134
Abstract
To explain the pathophysiological significance of endogenous atrial natriuretic polypeptide (ANP) in the development of hypertension, we examined the effect of chronic, repetitive administrations of MAb raised against alpha-rat ANP in two rat models of hypertension, spontaneously hypertensive rats of the stroke prone substrain (SHR-SP), and deoxycorticosterone acetate (DOCA)-salt rats. Weekly intravenous administrations of MAb with high affinity for alpha-rat ANP, named KY-ANP-II (MAb[KY-ANP-II]), started at the age of 6 wk, significantly augmented the rise in blood pressure of SHR-SP, compared with control SHR-SP treated with another MAb with quite low affinity for alpha-rat ANP, named KY-ANP-I (MAb[KY-ANP-I]), throughout the observation period. The administrations of MAb[KY-ANP-II] had no significant effect on blood pressure of age-matched normotensive Wistar Kyoto rats, compared with those receiving MAb[KY-ANP-I]. Weekly administrations of MAb[KY-ANP-II] also significantly aggravated hypertension in DOCA-salt rats. Blood pressure of DOCA-salt rats treated with MAb[KY-ANP-II] was significantly higher than that of DOCA-salt rats treated with MAb[KY-ANP-I] throughout 8 wk of DOCA and 1% saline administration. The administration of MAb[KY-ANP-II] also significantly attenuated exaggerated diuresis and natriuresis in DOCA-salt rats compared with those treated with MAb[KY-ANP-I]. Elevated plasma cGMP levels of both SHR-SP and DOCA-salt rats were significantly reduced by the administration of MAb[KY-ANP-II]. These results suggest the compensatory role of augmented secretion of ANP in these hypertensive rats and support the concept that augmented secretion of ANP could represent an antihypertensive deterrent mechanism.Keywords
This publication has 42 references indexed in Scilit:
- A monoclonal antibody to alpha-human atrial natriuretic polypeptide.Hypertension, 1988
- Simultaneous measurement of atrial natriuretic polypeptide (ANP) messenger RNA and ANP in rat heart — Evidence for a preferentially increased synthesis and secretion of ANP in left atrium of spontaneously hypertensive rats (SHR) —Biochemical and Biophysical Research Communications, 1987
- Secretory form of atrial natriuretic polypeptide as cardiac hormone in humans and ratsCanadian Journal of Physiology and Pharmacology, 1987
- Increased release of atrial natriuretic polypeptides in rats with DOCA-salt hypertensionLife Sciences, 1986
- Decreased content in left atrium and increased plasma concentration of atrial natriuretic polypeptide in spontaneously hypertensive rats (SHR) and SHR stroke-proneBiochemical and Biophysical Research Communications, 1986
- Changes in the content of atrial natriuretic factor with the progression of hypertension in spontaneously hypertensive ratsBiochemical and Biophysical Research Communications, 1985
- α-Human atrial natriuretic polypeptide is released from the heart and circulates in the bodyBiochemical and Biophysical Research Communications, 1985
- Radioimmunoassay for α-human and rat atrial natriuretic polypeptideBiochemical and Biophysical Research Communications, 1984
- Purification and complete amino acid sequence of α-human atrial natriuretic polypeptide (α-hANP)Biochemical and Biophysical Research Communications, 1984
- A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in ratsLife Sciences, 1981